Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14194MR)

This product GTTS-WQ14194MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14194MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14554MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ6252MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ5237MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ8755MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ3332MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ9429MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ4245MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ2085MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW